What Sent Aehr Test Systems (NASDAQ:AEHR) Up 26.5% as Revenue Tripled?

Vinay Lochav

05 November 2026 12:48 AM AEDT

What Sent Aehr Test Systems (NASDAQ:AEHR) Up 26.5% as Revenue Tripled?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Aehr Test Systems (NASDAQ:AEHR) gained 26.5% on November 3, 2026, after fiscal first-quarter Revenue of USD 33.0 million, up 200% from USD 11.0 million.
Bookings reached USD 46.7 million, a book-to-bill ratio of about 1.4, with Backlog of USD 100.9 million and effective backlog of USD 109.3 million at November 1, 2026.
Fiscal 2027 revenue guidance rose to USD 150 million from a USD 130 million to USD 150 million range, with non-GAAP Net Income of at least 20% of revenue.
GAAP net income was USD 7.2 million, or USD 0.21 a diluted share, and non-GAAP net income was USD 9.4 million, or USD 0.28, against a loss a year earlier.

What Aehr Reported

Aehr reported fiscal first-quarter 2027 results on November 2, 2026 for the quarter ended September 25. Revenue of USD 33.0 million was up 200% from USD 11.0 million and up 75% from USD 18.8 million in the prior quarter. GAAP net income came to USD 7.2 million, against a loss of USD 2.1 million a year earlier. Bookings were USD 46.7 million, and cash, cash equivalents and restricted cash totalled USD 105.1 million. The shares rose about 14% after hours on November 2 and closed 26.5% higher on November 3, according to published market data. Management said it sees production potential across more than a dozen customers, a claim that still needs to show up in orders. Aehr Test Systems (NASDAQ:AEHR) has moved from a small base to guiding toward USD 150 million of annual revenue.

Why Burn-In Testing Matters for AI

Burn-in testing applies heat and voltage to chips to expose early failures before they reach customers, which matters for costly AI processors. Aehr said a lead AI processor customer placed a USD 22 million follow-on order in August 2026, and a major AI accelerator supplier decided to buy a wafer-level burn-in cell for installation at an outsourced assembly and test partner in Taiwan, planned for early calendar 2027. A hyperscale customer is also installing package-level burn-in systems at more than a dozen a month. Guidance of USD 150 million implies about USD 117 million over the remaining three quarters, or about USD 39 million a quarter, simple arithmetic.

Risks and What to Watch Next

Aehr is a small company, so a few trades can move the price, spreads can be wide and quoted moves can reverse. A 26.5% move in one session does not mean the rise will continue. Revenue depends on a few large customers, so one delayed order could change results sharply. Cash fell to USD 105.1 million from USD 116.5 million at May 29, 2026. Investors will watch conversion of the USD 109.3 million effective backlog into revenue, orders beyond the lead customers and progress on the Taiwan installation planned for early 2027. Non-GAAP net income of at least 20% of revenue implies at least USD 30 million for the year, simple arithmetic.

Where Things Stand

Aehr surged 26.5% because revenue tripled, profit swung from a loss, bookings exceeded revenue and management lifted full-year revenue guidance to USD 150 million. The Business leans on a few AI customers, and as a small company its shares can move sharply on thin Volume and reverse just as fast. For Aehr Test Systems (NASDAQ:AEHR), converting backlog into revenue is the key test. The rally should not be read as a trend. Nothing here is Investment advice.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.